Table 8. KEGG analysis, LPS treated microglia.

Differentially expressed up and down-regulated proteins and phosphoproteins in baseline, untreated microglia. Additional file 7: Table S5.

KEGG pathway up-regulated proteins LPS microglia	p-value	KEGG pathway down-regulated proteins LPS microglia	p-value
Lysosome	2.38E-22	Spliceosome	6.00E-15
Metabolic pathways	1.22E-13	Nucleocytoplasmic transport	2.12E-13
Huntington disease	6.41E-12	Amyotrophic lateral sclerosis	1.68E-12
Parkinson disease	1.14E-11	Salmonella infection	1.86E-12
Prion disease	5.47E-11	Ribosome	1.15E-10
Amyotrophic lateral sclerosis	5.06E-10	Protein processing in endoplasmic reticulum	2.03E-10
Oxidative phosphorylation	1.25E-09	Epstein-Barr virus infection	2.74E-10
Chemical carcinogenesis - reactive oxygen species	4.44E-08	Carbon metabolism	1.08E-09
Pathways of neurodegeneration - multiple diseases	5.90E-08	Shigellosis	1.67E-09
Neutrophil extracellular trap formation	6.17E-08	Leishmaniasis	2.50E-08
Proteasome	1.43E-07	Metabolic pathways	2.64E-08
		Coronavirus disease - COVID-19	3.92E-08
		Influenza A	7.27E-08
KEGG pathway up-regulated phosphoproteins LPS microglia	p-value	KEGG pathway down-regulated phosphoproteins LPS microglia	p-value
Rap1 signaling pathway	6.29E-06	Spliceosome	2.07E-09
Yersinia infection	7.87E-06	Regulation of actin cytoskeleton	7.01E-07
Platelet activation	8.81E-06	Viral life cycle - HIV-1	7.27E-05
Regulation of actin cytoskeleton	7.58E-05	Thyroid hormone signaling pathway	9.62E-05
Fc gamma R-mediated phagocytosis	1.78E-04	ErbB signaling pathway	1.37E-04
Adherens junction	2.10E-04	Shigellosis	1.59E-04
Shigellosis	2.24E-04	Insulin signaling pathway	1.78E-04
Pathogenic Escherichia coli infection	2.59E-04	Rap1 signaling pathway	3.22E-04
Thyroid hormone signaling pathway	4.00E-04	Leukocyte transendothelial migration	4.17E-04
Chemokine signaling pathway	5.52E-04	Yersinia infection	5.00E-04